Paula Green Sells 935 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 935 shares of Twist Bioscience stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $46.43, for a total transaction of $43,412.05. Following the completion of the transaction, the senior vice president directly owned 124,401 shares in the company, valued at approximately $5,775,938.43. The trade was a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Paula Green also recently made the following trade(s):

• On Tuesday, February 3rd, Paula Green sold 1,194 shares of Twist Bioscience stock. The stock was sold at an average price of $46.58, for a total transaction of $55,616.52.
• On Monday, December 22nd, Paula Green sold 273 shares of Twist Bioscience stock. The shares were sold at an average price of $34.56, for a total transaction of $9,434.88.

Twist Bioscience Price Performance

NASDAQ TWST opened at $46.86 on Thursday. The firm’s fifty day simple moving average is $44.49 and its two-hundred day simple moving average is $35.00. The firm has a market capitalization of $2.87 billion, a P/E ratio of -36.61 and a beta of 2.23. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $57.88.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The business had revenue of $103.70 million during the quarter, compared to analyst estimates of $100.32 million. Twist Bioscience’s revenue for the quarter was up 16.9% on a year-over-year basis. Analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the subject of several research analyst reports. Barclays increased their price objective on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, February 3rd. Evercore raised their price target on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Robert W. Baird set a $50.00 target price on Twist Bioscience in a research report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.88.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently bought and sold shares of the business. Stifel Financial Corp boosted its holdings in shares of Twist Bioscience by 3.6% in the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after acquiring an additional 271 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Twist Bioscience by 1.2% during the fourth quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares during the last quarter. CWM LLC lifted its position in Twist Bioscience by 9.4% during the fourth quarter. CWM LLC now owns 4,738 shares of the company’s stock valued at $150,000 after purchasing an additional 407 shares during the period. Smartleaf Asset Management LLC boosted its holdings in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Twist Bioscience by 0.8% in the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after purchasing an additional 442 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.